We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-11.51%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$101M
AUM Growth
-$17.5M
Cap. Flow
-$4.67M
Cap. Flow %
-4.63%
Top 10 Hldgs %
44.39%
Holding
99
New
23
Increased
11
Reduced
26
Closed
11

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$1.8M
2
EPIX
ESSA Pharma
EPIX
+$1.59M
3
NEOS
Neos Therapeutics, Inc
NEOS
+$1.4M
4
WINT
Windtree Therapeutics Inc
WINT
+$1.28M
5
ABEO icon
Abeona Therapeutics
ABEO
+$965K

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.03M
2
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$1.66M
3
ATRC icon
AtriCure
ATRC
+$1.52M
4
DERM
Dermira, Inc.
DERM
+$832K
5
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 74.78%
2 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
51
Amgen
AMGN
$208B
$512K 0.51%
+3,700
New +$583K
VTVT icon
52
vTv Therapeutics
VTVT
$127M
$489K 0.49%
+1,875
New +$653K
CGNT
53
DELISTED
Cogentix Medical, Inc.
CGNT
$436K 0.43%
351,781
-1,400
-0.4% -$2.15K
TBRA
54
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$436K 0.43%
+45,092
New +$633K
LMNS
55
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$430K 0.43%
31,072
– –
ICPT
56
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$403K 0.4%
2,430
+430
+22% +$94.6K
CRDC
57
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$379K 0.38%
140,276
-8,324
-6% -$33.2K
GYRE icon
58
Gyre Therapeutics
GYRE
$641M
$330K 0.33%
630
+41
+7% +$62.5K
TNDM icon
59
Tandem Diabetes Care
TNDM
$1.34B
$322K 0.32%
3,655
+56
+2% +$6.52K
MBAI
60
Check-Cap
MBAI
$8.19M
$307K 0.3%
458
– –
TENX icon
61
Tenax Therapeutics
TENX
$363M
$245K 0.24%
+3
New +$343K
GNVC
62
DELISTED
GenVec, Inc.
GNVC
$221K 0.22%
9,580
-420
-4% -$10K
XENE icon
63
Xenon Pharmaceuticals
XENE
$6.06B
$207K 0.21%
+25,000
New +$248K
LOXO
64
DELISTED
Loxo Oncology, Inc
LOXO
$205K 0.2%
11,745
-500
-4% -$9.78K
RIOT icon
65
Riot Platforms
RIOT
$7.63B
$200K 0.2%
81,300
-950
-1% -$3.14K
ALPN
66
DELISTED
Alpine Immune Sciences Inc
ALPN
$195K 0.19%
3,750
– –
MRNS
67
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$186K 0.18%
5,580
– –
SRRA
68
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$174K 0.17%
+213
New +$240K
ATNM icon
69
Actinium Pharmaceuticals
ATNM
$26.3M
$159K 0.16%
3,000
– –
TRVN
70
DELISTED
Trevena, Inc.
TRVN
$153K 0.15%
+24
New +$118K
ETRM
71
DELISTED
EnteroMedics Inc.
ETRM
$130K 0.13%
+476
New +$152K
CASM
72
DELISTED
CAS Medical Systems, Inc.
CASM
$108K 0.11%
86,768
-1,754
-2% -$2.08K
CASC
73
DELISTED
Cascadian Therapeutics, Inc.
CASC
$99K 0.1%
6,030
– –
CEMI
74
DELISTED
Chembio diagnostics, Inc.
CEMI
$88K 0.09%
21,722
-4,565
-17% -$20.7K
CVM icon
75
CEL-SCI Corp
CVM
$20.3M
$84K 0.08%
186
-236
-56% -$108K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, DAFNA Capital Management held 99 positions worth $101M, down 15% from $118M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

DAFNA Capital Management withdrew a net $4.67M in Q3 2015, closing 11 positions and reducing 26 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $2.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Adverum Biotechnologies worth $1.16M.

  • DAFNA Capital Management's largest Q3 2015 buy was Adverum Biotechnologies: 14,060 shares worth $1.16M.
  • DAFNA Capital Management added most to Windtree Therapeutics Inc in Q3 2015, an estimated $1.28M increase.
  • DAFNA Capital Management's biggest Q3 2015 reduction was AtriCure, cutting an estimated $1.52M.
  • DAFNA Capital Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $2.03M.
  • DAFNA Capital Management's ten largest holdings make up 44% of its $101M portfolio in Q3 2015.
  • DAFNA Capital Management opened 23 new positions and closed 11 in Q3 2015.
  • DAFNA Capital Management's portfolio value fell 15% quarter-over-quarter to $101M.

Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.